



**apma** >  
Advancing foot and ankle  
medicine and surgery

Online  
CECH

# Dermatologic Manifestations of COVID-19

# Dermatologic Manifestations of COVID-19

- APMA is approved by the Council on Podiatric Medical Education as a provider of continuing education in podiatric medicine.
- This activity has been approved for a maximum of 0.5 continuing education contact hour.
- To support this webinar, APMA has designated an unrestricted educational grant from Bako Diagnostics.


# Learning Objectives

- To discuss the findings in the literature and how that relates to podiatric medicine.
- To review skin manifestations of viral diseases.

# Speaker

## Tracey Vlahovic, DPM

- Clinical Professor, Temple University School of Podiatric Medicine, Department of Podiatric Medicine
- Adjunct Professor, Temple University School of Medicine, Department of Microbiology



# What I will cover:

**Chilblains (Pernio)**

**Dermatologic manifestations of viral disease**

**COVID-19 skin manifestations in the literature**

# Chilblains

- Inflammation of the acral vessels
- Resolves in 1-3 weeks, or when exposed to warmer temps
- Exact cause unknown, but can be associated with numerous disorders



# Working up Chilblains (Pernio)

**Common, self-limiting, acral involvement**

**Study of 104 patients: Women>men, mean age 38, but age range of 6-80, current or former smokers, Raynaud's**

**Affects the toes 82%**

**About 25% had no symptoms except the skin change**

**63% had no abnormal lab tests; cryoglobulins negative**

**Does not need cold weather; can be from sweating or exposure to water; can be associated with water, but some have pernio without cold or wet conditions**

# Working up Chilblains (Pernio)

Need the major and one minor:

**One major criterion:** localized erythema and swelling involving acral sites and persisting for >24 hrs

**Three minor criteria:**

- 1) onset or worsening in cooler months (Nov to March),
- 2) biopsy results show pernio (in absence of lupus),
- 3) response to conservative care (warming, drying area)

# Treatment of Chilblains

**Differential Diagnoses: vasculitis, lupus, cutaneous thromboemboli**

**Use criteria, do thorough history**

If no underlying associated systemic condition, no need for skin biopsy and lab studies

If criteria aren't met, skin biopsy warranted

If ROS suggestive, do lab work up

**Warming, drying, smoking cessation**

**Topical steroids if pruritic; Systemic therapies (pentoxifylline, aspirin)**

# Chilblains in Spain

## Landa et al in International J Dermatology

- **Commentary from Spanish dermatologists of chilblain-like lesions with no Raynaud's or ischemia**
- **Reddish papules that became purpuric and flattened**
  - **Mild pain, Resolved on their own**
- **6 cases ranging from 15 y.o. to 91 y.o.**
  - **All but one was symptomatic systemically**
  - **Only 2 tested positive for COVID-19**

# Chilblains in Spain

**No skin biopsies were done**

**Hypothesis: a “late stage” manifestation of COVID-19**

**-due to the amount of cases seen after the peak of infections in Spain, Italy, France**

**“The lack of confirmatory testing does not allow us to corroborate the association of these type of lesions with COVID-19”**

**however, the high number of consultations...**

**“Until further confirmation that these lesions are related to COVID-19, we must be cautious and recommend general measures of social distance, hygiene, self-isolation, and surveillance”**

# Skin lesions from Landa et al article

doi: 10.1111/ijd.14937



# Chilblains in Italy

## Piccolo et al, Letter to the editor, in JEADV

**Chilblain-like lesions**

**Preliminary results of 63 patients from a google doc form**

**Median age 14, feet alone affected 85.7%, erythematous lesions with pain, itch, and some blisters**

**In addition, GI symptoms, respiratory, fever**

**Swab performed in 11 pts, only 2 positive**

**One was positive for mycoplasma pneumoniae, and parvo B19 high rate**

**Auto-immune disorders in 6; some had positive co-habitants**

# Chilblains in Italy

## Defined as Chilblains-Like Lesions (CLL)

**Hypothesis: coronavirus is responsible**

**Testing difficult to do as most were asymptomatic**

**“As concerning etiology, we are still far from scientifically defining CLL as a manifestation of COVID- 19”**

**Delayed immune reaction to the virus**

**“Children...with skin manifestations...should be considered contagious”**

# Acro-ischemia

## Digital gangrene, bullae, cyanosis

- Zhang et al 7 COVID-19 pts from Wuhan: DIC, hypercoagulable state
- Fernandez-Nieto retrospective review of 132 patients in Spain
  - 2/11 diagnosed with COVID-19 via nasal swab
  - 16 had symptoms before skin lesions (range 3-30 days)
  - skin lesions lasted 2-24 days; none had pneumonia
    - chilblains-like in 95 pts; erythema multiforme-like in 37 pts
    - late manifestation, coagulation disorder, or hypersensitivity?

# Skin and Viral Infections

## Viral infections cause skin issues/exanthems

- Prodrome first: fever, malaise, headache, GI
- Measles, rubella, chickenpox/shingles, dengue fever, fifth dx, pityriasis rosea, hand/foot/mouth dx, viral warts, vasculitis (seen in Influenza, HIV, Hep B and C), Kaposi's sarcoma (HHV-8), urticaria (hives)
- Viremia and skin exanthems have different time kinetics in different diseases:
  - viremia of measles peaks when skin rash presents
  - viremia of parvovirus B19 ends before skin rash begins

# Coronavirus and the skin

## Coronavirus has been around for centuries...

**Chesser et al reported an 8-month-old with fever, mild cough, progressive purpura and extremity swelling that extended from thighs to feet**

**Acute hemorrhagic edema of infancy (leukocytoclastic vasculitis) and often preceded by viral infection; resolution in 3 days**

**Positive for coronavirus NL63**

# Coronavirus and the skin

## Novel coronavirus SARS-CoV-2 is the cause of COVID-19

-Unknown prevalence and pattern of COVID-19 viral exanthem

-Is there anything that differentiates it from other viral rashes?

-At this point, characteristics like many other viral infections

**-20% have skin lesions?**                      THIS IS NOT FROM A STUDY!

-It comes from Recalcati's JEADV article showing 20% (18/88 pts) had trunk lesions: red rash and chickenpox-like

-8 had lesions at onset, 10 after hospitalization

# Coronavirus and the skin

## Reports from around the world:

**Tammaro et al (Italy) JEADV: 3/130 pts had herpetic-like lesions on trunk**

**Manalo et al JAAD: had 2 cases of confirmed COVID-19 and transient livedo reticularis**



<https://doi.org/10.1111/jdv.16387>

<https://doi.org/10.1016/j.jaad.2020.04.018>

# Coronavirus and the skin

## Reports from around the world:

**JEADV: 14 COVID-19 confirmed patients**

**Skin symptoms began after COVID-19 symptoms**

**7/14=exanthem**

**7/14=violaceous macules**

**2/14=chilblains**

**BUT...40 others had chilblains like lesions and tested negative (6) or not performed. Are these due to something else?, A post-viral immunologic response?, or Represent a subgroup with a peculiar immune anti-viral response?**

# What are the issues with these reports, commentaries, letters to the editor?

- Due to the regulations in place, COVID testing may not have been performed, so correlation is speculative in many of these papers. Data over time will help with this.
- Often no pictures or histopathologic correlation. Most have been listed on the journal website due to timeliness and may not have had a thorough peer review.
- Many viral infections cause skin manifestations. These reports show heterogeneity. They raise more questions than provide answers.

# What are the issues with these reports, commentaries, letters to the editor?

- Underlying systemic issues or medications may cause skin lesions, so imperative to rule those out.
- The difference between those who are in respiratory distress vs those who are asymptomatic. Read the literature critically. Don't go by hearsay.
- It is good to be vigilant that this may exist, but don't put your blinders on and think every skin rash source is coronavirus. Consider appropriate differential diagnoses.

# Coronavirus affecting other skin conditions

- Psoriasis--biologic therapy and risk of being in an “immunocompromised state”
- Atopic Dermatitis--frequent hand washing/hand sanitizers causing flares and face mask irritation
- Melanoma—delays in diagnosis and clinical trials halted
- Vitamin D deficiency and majority of time being spent indoors
- Cosmetic procedures

# “COVID-toes” or people are looking at their feet more than usual

What is the actual correlation between the pedal manifestations and COVID-19, if any? If so, what is the percentage of occurrence, timing, and its relation to severity of disease? Does age play a role?

Will these pedal lesions help diagnose COVID-19 in those who are asymptomatic? Must consider ethics/testing supplies. Will this change the course of treatment if self-isolation is in place? Are the patients still infectious to others? Should this be added to criteria for COVID-19 testing?

So far, the cases I have seen and been sent (>20), only 1 person has tested COVID-19 positive. Hypotheses?

# Key Points to Consider

-Thorough History and Physical Exam are key

-Timing of when lesions occurred with any symptoms

-Evolution of lesions, Extent of presentation

-Asymptomatic vs Being Hospitalized

Hypercoagulable state, DIC, respiratory distress

-PMH, Medications, Contacts who are symptomatic or are COVID-19 positive

-Biopsy of skin if warranted, Dynamic viral load collection and its timing to skin rash

-Regulations for COVID-19 testing in your area

# In your practice

- When faced with a patient who has skin manifestations that have a high index of suspicion, be a detective, thorough, and logical in your assessment
- Do appropriate testing if warranted (lab tests, skin biopsy)
- If no other diagnosis fits the clinical picture, you may consider COVID-19 as a differential diagnosis. Patient should follow CDC and local guidelines of social distancing, self-isolation, and self-monitoring
- Depending on your local regulations and discussion with the patient, you may consider viral testing or in some cases antibody testing

# Last word

**“While better testing for COVID-19 and more lesion biopsies will play a critical role in differentiating etiologies, we must not overcall COVID-19–related skin eruptions and potentially overlook other diagnoses,”**

**The goal is "to better determine COVID-19 pathophysiology, systemic associations, patient outcomes, and potential therapeutics."**

**--Dr. Kristen Lo Sicco, Dermatologist, NYU**



**apma** > | Online  
Advancing foot and ankle  
medicine and surgery | CECH

**Questions?**

**Thank you!**